107 related articles for article (PubMed ID: 8249432)
21. Very small size proteoliposomes derived from Neisseria meningitidis: An effective adjuvant for generation of CTL responses to peptide and protein antigens.
Mesa C; de León J; Fernández LE
Vaccine; 2006 Mar; 24(14):2692-9. PubMed ID: 16316710
[TBL] [Abstract][Full Text] [Related]
22. Augmented humoral and cellular immune responses of a hepatitis B DNA vaccine encoding HBsAg by protein boosting.
Xiao-wen H; Shu-han S; Zhen-lin H; Jun L; Lei J; Feng-juan Z; Ya-nan Z; Ying-jun G
Vaccine; 2005 Feb; 23(14):1649-56. PubMed ID: 15705468
[TBL] [Abstract][Full Text] [Related]
23. Comparison of the adjuvanticity of aluminum salts and their combination in hepatitis B recombinant protein vaccine in assessed mice.
Mahboubi A; Fazeli MR; Dinarvand R; Samadi N; Sharifzadeh M; Ilka H; Azadi S; Soleimanian R; Kalkouei H; Hajikhanmirzaei R; Valadkhani M
Iran J Immunol; 2008 Sep; 5(3):163-70. PubMed ID: 18791283
[TBL] [Abstract][Full Text] [Related]
24. Effect of adjuvant composition on immune response to a multiple antigen peptide (MAP) containing a protective epitope from Neisseria meningitidis class 1 porin.
Christodoulides M; Rattue E; Heckels JE
Vaccine; 1999 Aug; 18(1-2):131-9. PubMed ID: 10501243
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity of in vitro folded outer membrane protein PorA of Neisseria meningitidis.
Jansen C; Kuipers B; van der Biezen J; de Cock H; van der Ley P; Tommassen J
FEMS Immunol Med Microbiol; 2000 Mar; 27(3):227-33. PubMed ID: 10683467
[TBL] [Abstract][Full Text] [Related]
26. Enhanced immunogenicity of a sequence derived from hepatitis B virus surface antigen in a composite peptide that includes the immunostimulatory region from human interleukin 1.
Rao KV; Nayak AR
Proc Natl Acad Sci U S A; 1990 Jul; 87(14):5519-22. PubMed ID: 2371286
[TBL] [Abstract][Full Text] [Related]
27. Humoral hyporesponsiveness to a conjugate contraceptive vaccine and its bypass by diverse carriers using permissible adjuvant.
Mandokhot A; Pal R; Nagpal S; Chauhan VS; Ahlawat S; Singh O
Clin Exp Immunol; 2000 Oct; 122(1):101-8. PubMed ID: 11012625
[TBL] [Abstract][Full Text] [Related]
28. Additive effects of CpG ODN and R-848 as adjuvants on augmenting immune responses to HBsAg vaccination.
Ma R; Du JL; Huang J; Wu CY
Biochem Biophys Res Commun; 2007 Sep; 361(2):537-42. PubMed ID: 17662694
[TBL] [Abstract][Full Text] [Related]
29. Humoral responses against coimmunized protein antigen but not against alphavirus-encoded antigens require alpha/beta interferon signaling.
Hidmark AS; Nordström EK; Dosenovic P; Forsell MN; Liljeström P; Karlsson Hedestam GB
J Virol; 2006 Jul; 80(14):7100-10. PubMed ID: 16809315
[TBL] [Abstract][Full Text] [Related]
30. Effect of adjuvants in the isotypes and bactericidal activity of antibodies against the transferrin-binding proteins of Neisseria meningitidis.
Gómez JA; Hernández E; Criado MT; Ferreirós CM
Vaccine; 1998 Oct; 16(17):1633-9. PubMed ID: 9713939
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine.
Donnelly JJ; Deck RR; Liu MA
J Immunol; 1990 Nov; 145(9):3071-9. PubMed ID: 2120344
[TBL] [Abstract][Full Text] [Related]
32. Binding immune-stimulating oligonucleotides to cationic peptides from viral core antigen enhances their potency as adjuvants.
Riedl P; Buschle M; Reimann J; Schirmbeck R
Eur J Immunol; 2002 Jun; 32(6):1709-16. PubMed ID: 12115654
[TBL] [Abstract][Full Text] [Related]
33. RNA is an Adjuvanticity Mediator for the Lipid-Based Mucosal Adjuvant, Endocine.
Hayashi M; Aoshi T; Ozasa K; Kusakabe T; Momota M; Haseda Y; Kobari S; Kuroda E; Kobiyama K; Coban C; Ishii KJ
Sci Rep; 2016 Jul; 6():29165. PubMed ID: 27374884
[TBL] [Abstract][Full Text] [Related]
34. Induction of virus-neutralizing antibodies by bacteria expressing the C3 poliovirus epitope in the periplasm. The route of immunization influences the isotypic distribution and the biologic activity of the antipoliovirus antibodies.
LeClerc C; Martineau P; Van der Werf S; Deriaud E; Duplay P; Hofnung M
J Immunol; 1990 Apr; 144(8):3174-82. PubMed ID: 2157762
[TBL] [Abstract][Full Text] [Related]
35. Posintro™-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses.
Schiött A; Larsson K; Manniche S; Kalliomäki S; Heydenreich AV; Dalsgaard K; Kirkby N
Int J Pharm; 2011 Jul; 414(1-2):312-20. PubMed ID: 21601626
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of monoamine oxidase by esters and peptides of aromatic amino acids.
Pozdnev VF; Pekkel' VA; Aksenova LN
Biomed Sci; 1990 Mar; 1(3):288-90. PubMed ID: 2103832
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant effect of CIA07, a combination of Escherichia coli DNA fragments and modified lipopolysaccharides, on the immune response to hepatitis B virus surface antigen.
Song ES; Park SA; Kim SH; Cho YJ; Ahn BY; Ahn BC; Lee NG
FEMS Immunol Med Microbiol; 2007 Dec; 51(3):496-504. PubMed ID: 17877731
[TBL] [Abstract][Full Text] [Related]
38. A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.
Egan MA; Chong SY; Hagen M; Megati S; Schadeck EB; Piacente P; Ma BJ; Montefiori DC; Haynes BF; Israel ZR; Eldridge JH; Staats HF
Vaccine; 2004 Sep; 22(27-28):3774-88. PubMed ID: 15315859
[TBL] [Abstract][Full Text] [Related]
39. Evidence for adjuvanticity of anthrax edema toxin.
Quesnel-Hellmann A; Cleret A; Vidal DR; Tournier JN
Vaccine; 2006 Feb; 24(6):699-702. PubMed ID: 16168529
[TBL] [Abstract][Full Text] [Related]
40. Induction by synthetic peptides of broadly reactive, type-specific neutralizing antibody to poliovirus type 3.
Ferguson M; Evans DM; Magrath DI; Minor PD; Almond JW; Schild GC
Virology; 1985 Jun; 143(2):505-15. PubMed ID: 2414909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
